We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Medivation, Astellas’ Xtandi for Prostate Cancer
FDA Approves Medivation, Astellas’ Xtandi for Prostate Cancer
September 7, 2012
Medivation and Astellas expect their oral prostate cancer treatment Xtandi will be available mid-September, following an Aug. 31 FDA approval.